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High energy demands of neurons make them vulnerable to adverse effects of energy impairment. Recently, astrocytes were shown to
regulate the fluxof energy substrates toneurons. Inpathological situations, astrocytes are activatedbut the consequencesonbrain energy
metabolism are still poorly characterized. We found that local lentiviral-mediated gene transfer of ciliary neurotrophic factor (CNTF), a
cytokine known to activate astrocytes, induced a stable decrease in the glycolytic flux in the rat striatum in vivo as measured by 2-[18F]-
2-deoxy-D-glucose autoradiography and micro-positron emission tomography imaging. The activity of the mitochondrial complex IV
enzyme cytochrome oxidase was not modified, suggesting maintenance of downstream oxidative steps of energy production. CNTF
significantly increased the phosphorylation level of the intracellular energy sensor AMP-activated protein kinase (AMPK), supporting a
specific reorganization of brain energy pathways. Indeed, we found that different key enzymes/transporters of fatty acids -oxidation
and ketolysis were overexpressed by CNTF-activated astrocytes within the striatum. In primary striatal neuron/astrocytemixed cultures
exposed to CNTF, the AMPK pathway was also activated, and the rate of oxidation of fatty acids and ketone bodies was significantly
enhanced. Thismetabolic plasticity conferred partial glial and neuronal protection against prolonged palmitate exposure and glycolysis
inhibition. We conclude that CNTF-activated astrocytes may have a strong protective potential to face severe metabolic insults.
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Introduction
Neurons have high energy needs and restricted internal energy
stores. They are therefore dependent on a tight regulation of
energy metabolism and supply. Astrocytes have a central role in
the regulation of brain energy metabolism. They send endfeet
around brain capillaries (Kacem et al., 1998), which allow them
to control the entry of energy substrates into brain parenchyma.
Glucose is, by far, the major brain energy substrate, and astro-
cytes participate in matching glucose supply to neuronal energy
needs (Pellerin and Magistretti, 1994; Voutsinos-Porche et al.,
2003). Other energetic blood-borne substrates, such as fatty acids
and ketone bodies, may also fuel brain function, depending on
their availability. Astrocytes are the only cell type able to perform
-oxidation of fatty acids in the brain (Edmond et al., 1987), a
catabolic pathway that may represent up to 20% of brain oxida-
tive energy production (Ebert et al., 2003). The rate of
-oxidation in astrocytes is under the tight control of the AMP-
activated protein kinase (AMPK) (Blazquez et al., 1999), a central
protein to promote a concerted regulation of many energy me-
tabolism pathways (Hardie et al., 2006). Astrocytes also use fatty
acids as precursors for the synthesis of ketone bodies that are
exchanged with neurons (Auestad et al., 1991; Guzman and
Blazquez, 2001). Indeed, ketone bodies also represent a major
fuel for the brain in specific conditions (Sokoloff, 1973).
In response to a wide range of pathological situations, astro-
cytes become reactive and display a very distinct phenotype (Kal-
man, 2004). These phenotypic changes are likely accompanied by
changes in their function that, in turn, may either be beneficial or
detrimental for brain recovery; this issue remains very controver-
sial. In addition, little is known about the metabolic conse-
quences of astrocyte activation, particularly in vivo.
To characterize themetabolic profile of reactive astrocytes, we
used our two previously described models of astrocyte activation
through either lentiviral-gene transfer of the cytokine ciliary neu-
rotrophic factor (CNTF) in the rat striatum in vivo or exposure of
primary neuron astrocyte mixed cultures to recombinant CNTF
(Escartin et al., 2006). CNTF induces a sustained activation of
astrocytes in a large part of the striatum, whereas neurons display
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a normal phenotype in terms of morphology, expression of neu-
ronal proteins, and spontaneous electrophysiological activity.
Many aspects of in vivo astrocyte activation are reproduced by the
exposure of primary mixed cultures to CNTF in vitro (Escartin et
al., 2006). Interestingly, in addition to its well known effects on
brain cells, CNTF is known to modify the metabolism of periph-
eral organs either directly (Sleeman et al., 2003; Watt et al.,
2006b) or through central effects mediated by the hypothalamus
(Gloaguen et al., 1997; Xu et al., 1998; Lambert et al., 2001).
We found that CNTF-induced astrocyte activation in the stri-
atum was associated with a marked rearrangement of metabolic
features. The metabolic plasticity of CNTF-activated astrocytes
significantly improved their ability to resist to metabolic insults,
ultimately providing protection to neurons.
Materials andMethods
Reagents and animals. All products come from Sigma (St. Louis, MO),
unless otherwise specified.
Three-month-old male Lewis rats (weight, 300 g; IFFA Credo,
L’Arbresle, France) were used for in vivo experiments. Embryos used for
primary cell cultures were taken from time pregnant SpragueDawley rats
(Janvier, Le Genest, France). All surgical procedures were performed in
strict accordance with the recommendations of the European Commu-
nities Council (86/609/EEC) and in conformity with the Swiss national
institutional guidelines on animal experimentation.
Stereotaxic injections of lentiviruses in the rat striatum. Rats received
stereotaxic injections of self-inactivated lentiviruses that encode either
the human CNTF c-DNA (lenti-CNTF) with the export sequence of
immunoglobulin or the-galactosidase gene (lenti-LacZ) under the con-
trol of the mouse phosphoglycerate kinase 1 promoter, as described previ-
ously (Escartin et al., 2006). The production and characteristics of these
lentiviruses have been described previously (Escartin et al., 2006). Rats were
either injected with different viruses or vehicle (Veh; PBS plus 1% BSA) in
each striatum (lenti-CNTF/lenti-LacZ and lenti-LacZ/Veh rats) or injected
bilaterally with the same virus or vehicle (lenti-CTF, lenti-LacZ, and Veh
Figure 1. CNTF reduces glucose uptake in vivo. A, Vimentin immunostaining of rat brain sections after intrastriatal injection of lentiviruses encoding either CNTF or LacZ. CNTF induces the
expression of vimentin comparedwith the control striatum injectedwith lenti-LacZ.B, Measurement of striatal FDG uptake in vivowas performed using the autoradiographic technique. A decrease
in FDG uptake (mean of17%) is observed in the whole lenti-CNTF-injected striatum. There is no significant difference between Veh and lenti-LacZ-injected striata for FDG uptake. C, Example of
an FDG–PET scan obtained at 4 months after lenti-CNTF injection. After image reconstruction, PET scans were overlaid with anatomical magnetic resonance images for drawing regions of interest
from striatum (red: LacZ; blue: CNTF). The curve represents a typical time course of FDG accumulation in both regions and shows a reduced FDG uptake in the CNTF-injected striatum. Data are
expressed as mean SEM; ***p 0.001; Student’s paired t test; n 6 per group.
Figure 2. CNTF decreases the activity of the glycolytic enzyme LDH but does not affect
oxidative phosphorylation in vivo. A, LDH activity is slightly decreased by 11% in the striatum
injected with lenti-CNTF, as evidenced on brain sections processed for LDH histochemistry. B,
CNTFoverexpressionhasnoeffect on striatal oxidativemetabolismas shownbyCOXhistochem-
istry. Data are expressed asmean SEM; **p 0.01; Student’s paired t test; n 6 per group.
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rats). Experiments were performed between 15 d and 6 months after infec-
tion, because the activation of astrocytes by CNTF was demonstrated to be
stable over this period (Escartin et al., 2006).
Primary striatal neuron/astrocyte cultures. Primary striatal neuron/as-
trocyte mixed cultures were prepared from embryonic day 14 (E14) to
E15 rat embryos as described previously (Escartin et al., 2006) and grown
in complete Neurobasal medium [serum-free Neurobasal medium sup-
plemented with 2% B27 (Invitrogen, Carlsbad, CA), 1% antibiotic-
antifungal mixture (Invitrogen), and 0.5 mM L-glutamine]. Human re-
combinant CNTF (R&DSystems,Minneapolis,MN)was diluted in PBS
and 0.1% BSA at a stock concentration of 25 g/ml. CNTF (50 ng/ml;
dilution, 1/500) was added at 15 d in vitro (DIV) and at 17 DIV. Control
wells were treated with vehicle (final concentration, 2.5 g/ml BSA in
PBS). Cell cultures were studied at 19 DIV.
Western blots. The striatum of lenti-CNTF, lenti-LacZ, or Veh rats
(n 4–5 per group) was rapidly dissected out on ice. Tissue samples and
cell cultures were homogenized, and Western blots were made as de-
scribed previously (Herard et al., 2005) using the ECL detection tech-
nique (GE Healthcare, Little Chalfont, UK). Films were scanned, and
optical density was measured and normalized to actin. The antibodies
used were raised against actin (1:10,000), AMPK (1:500; Cell Signaling,
Beverly, MA), phospho-AMPK (Thr172, 1:1000; Cell Signaling), and
glucose transporter 1 (Glut-1, 1: 500; Calbiochem, La Jolla, CA).
Immunochemistry. Brains sections and cell cultures were processed for
double-labeling immunochemistry as described previously (Escartin et
al., 2006) and were studied with confocal microscopy using a Zeiss
(Oberkochen, Germany) confocal microscope.
The antibodies used were as follows: -hydroxybutyrate dehydroge-
nase (BDH, 1:250; a kind gift from Prof. Latruffe, Universite´ de Dijon,
Dijon, France), carnityl-palmityl transferase 1 (CPT1, 1:500; a kind gift
from Dr. Prib-Buus, Cochin Institute, Paris, France), GFAP (1:500;
Dako, Carpinteria, CA), microtubule-associated protein 2 (MAP2;
1:200), nestin (1:500), succinyl-CoA:3-oxoacid CoA-transferase (SCOT;
1:500, a kind gift from Dr. Murad, University of Texas, Austin, TX),
S100 (1:1000), and vimentin (1:1000; Calbiochem). Vimentin and
monocarboxylate transporter 1 (MCT1) immunochemistry were per-
formed as described previously (Pierre et al., 2000; Escartin et al., 2006).
Histochemistry.Histochemistry of lactate dehydrogenase (LDH), cyto-
chrome oxidase (COX), and BDH were performed according to the
method of Dufour et al. (2003), Greene and Greenamyre (1995), and
Bilger and Nehlig (1992), respectively. Coronal brain sections were cut
from frozen brains of lenti-CNTF/lenti-LacZ and Veh/lenti-LacZ rats
(n  7 per group) using a cryostat and were stored immediately at
80°C. Six serial sections (interspace, 100 m) from each animal were
processed for histochemistry of each enzyme. Nonspecific staining was
obtained by incubating successive sections (three animals per group)
without substrate. Sections were digitized and striatal optical densities
were measured. Specific activity was calculated as the difference between
total and nonspecific staining.
Determination of glucose plasma concentrations. Lenti-CNTF, Lenti-
LacZ, andVeh rats (n 4–6 per group) were anesthetized and a catheter
implanted in the femoral artery. Glucose concentration was determined
on arterial blood samples using a OneTouch glucose meter (Lifescan,
Milpitas, CA) after night fasting.
In vivo 2-[18F]-deoxy-D-glucose uptake. Glucose uptake was assessed
on lenti-CNTF/lenti-LacZ rats and Veh/lenti-LacZ (n  6 per group).
Rats received an intraperitoneal injection of 2-[ 18F]-2-deoxy-D-glucose
(FDG; 1–1.7 mCi in 1 ml of normal saline) and were allowed to move
freely during the experiment. Forty-five minutes after FDG injection,
brains were cut into 20 m sections with a cryostat and processed for
4
Figure 3. CNTF activates AMPK and increases CPT1 expression in astrocytes in vivo. A, CNTF
induces a strong increase in the level of phosphorylationofAMPKwithout altering the total level
of expression of AMPK in the rat striatum. B, In the CNTF-injected striatum, cells with a strong
labeling for CPT1 (green) are observed; they coexpress vimentin (red) but not the neuronal
protein NeuN (red). Scale bar, 20 m. Blots and images are representative of four to five
animals per group.
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autoradiography. Autoradiograms were digi-
tized and striatal optical densities were mea-
sured on 10 successive sections for each animal.
To investigate long-term metabolic effect of
CNTF, noninvasive imaging studies of glucose
uptake by micro-positron emission tomogra-
phy (PET; Concorde Focus200 PET scanner)
were repeated at 4 weeks and 4 months after
injection on lenti-CNTF/lenti-lacZ rats (n 6).
Rats were anesthetized with a mixture of ket-
amine (15 mg/kg) and xylazine (1.5 mg/kg),
and a catheter was introduced into the tail vein
for administration of FDG (2–3.5 mCi). Ani-
mals were mounted onto a home-made stereo-
taxic frame compatible with PET acquisition to
allow accurate repositioning of the animal in
longitudinal studies. Dynamic accumulation of
radioactivity into the brain was acquired for 60
min. After image reconstruction, PET images
were overlaid with anatomical magnetic reso-
nance images for drawing three-dimensional
(3D) regions of interest from the striatum.
Magnetic resonance imaging studies were con-
ducted in awhole-body 3T systemwith a home-
built, transmit/receive bird-cage coil. Inversion
recovery fast spin echo T2-weighted 3D images
were recorded using the following parameters:
repetition time, 2000 ms; echo time (TE), 10.1
ms; weighted TE, 79.4 ms; rare factor, 16; field
of view, 3.84 3.84 3.84 cm3; matrix, 128
128 128; resolution, 300 300 300 m3.
In vitro oxidation of [14C]-3-hydroxybutyrate to 14CO2.Mixed cultures
grown on plastic petri dishes (diameter, 35 mm) were switched to
DMEM supplemented with 1 mM D-glucose, 5 mM HEPES, 7.5 mM
NaHCO3, and antibiotic–antifungal mixture (DMEM1) for 1 h. Cells
were then incubated in DMEM1 with 2 mM 3-hydroxybutyrate (BHB)
plus 0.4 Ci/ml [ 14C]-BHB (specific activity, 35 mCi/mmol;
PerkinElmer, Boston, MA) in hermetic vials. After 50 min, CO2 was
released from the medium through acidification by 0.5 ml of 0.2 M HCl.
CO2 was trapped by 1 ml Carbosorb (PerkinElmer), added in the cham-
ber outside the dish. After 1 h of equilibration, 450 l of Carbosorb was
taken in duplicate for scintillation counting. Background level was eval-
uated on cells lysed by 1% Triton X-100 before incubation in the same
medium. The inhibitor of MCTs -cyano-4-hydroxy-
cinnamate (4-CIN)was added 20min before incubationwith radioactive
BHB at a concentration of 1.5 mM and maintained during the 50 min
incubation at a concentration of 3 mM. The production of 14CO2 was
normalized to the protein content of the dish and the background was
subtracted. Experiments weremade on three to four dishes per treatment
and repeated on four separate cultures.
In vitro oxidation of [14C]-palmitate to 14C-intermediate metabolites
and 14CO2. The same experiment was performed using [
14C(U)]-
palmitate as a substrate (0.4 Ci/ml; specific activity, 850 mCi/mmol;
PerkinElmer). Labeled palmitate was first mixed with albumin-bound
cold palmitate (BSA to palmitate molar ratio, 5:1) and then added to
DMEM1 and 0.5 mM L-carnitin (final concentration, 0.2 mM total palmi-
tate). At the end of a 2 h incubation period, the medium was acidified
with perchloric acid to precipitate proteins and albumin-bound palmi-
tate and to isolate the acid-soluble metabolites of palmitate (i.e., mainly
ketone bodies in addition to Krebs cycle intermediates and short-chain
fatty acids) (Blazquez et al., 1998). The acidified medium was collected,
centrifuged, and the radioactivity found in the supernatant was counted.
Sodium etomoxir, the inhibitor of CPT1, and 4-CIN were used at a
concentration of 40M and 3 mM, respectively. They were added 20 min
before incubation with 14C-palmitate and maintained throughout the
incubation period. Experiments weremade on two to five wells per treat-
ment and repeated on two to four separate cultures.
Exposure to palmitate. After a 72 h treatment with Veh or CNTF, cells
were exposed to 0.2mMBSA-boundpalmitate plus 0.5mM L-carnitine for
24 h in completeNeurobasalmedium. Some cells were exposed to palmi-
tate in the presence of 2 mM 4-pentenoate to inhibit -oxidation. Astro-
cytes and neurons were labeled with GFAP and MAP2, respectively.
4-pentenoate and BSA had no effect by themselves on the survival of
astrocytes and neurons (data not shown). Images were obtained from
two to three wells and repeated on three independent cultures.
Exposure to iodoacetate. After a 72 h treatment with Veh or CNTF, the
culture medium was collected, stored at 37°C, and replaced with 0.4 mM
iodoacetate (IAA) in complete Neurobasal medium, in the absence of
CNTF or Veh. After 10 min, cultures were returned to their previous
medium for 24 h. Control cultures were also subjected to this change of
medium. 4-CIN (3 mM final concentration) was added during the incu-
bation with IAA and the 24 h recovery period. 4-CIN alone did not have
any detectable effect on the survival of astrocytes and neurons (data not
shown). Total cell survival was quantified by counting DAPI-positive
nuclei on 13–21 randomly chosen fields taken at the 20 objective using
a motorized Zeiss Axioplan2 imaging microscope (Carl Zeiss, Vesinet,
France). Images were obtained from two to three wells and repeated on
three to six independent cultures for each treatment.
Statistical analysis. Results are expressed as mean values  SEM. Sta-
tistical analysis included unpaired Student’s t test and one-way ANOVA
followed by a post hoc F Scheffe´ test (when comparing two or three
groups, respectively). Student’s paired t test was performed for left–right
comparisons in vivo. The significance level was set at p 0.05.
Results
CNTF decreases striatal glycolysis in vivo
Wemeasured brain glucose uptake in the striatum using autora-
diography after injection of FDG. FDG uptake was not modified
by the injection of the lentivirus itself (no difference between
lenti-LacZ and Veh) (Fig. 1B). In the striatum injected with a
lentivirus encoding CNTF (lenti-CNTF), we found a consistent
decrease in FDG uptake compared with the contralateral stria-
tum injected with lenti-LacZ, 2 months after injection (17%;
p 0.001; Student’s paired t test) (Fig. 1B). The spatial extent of
decreased FDG uptake matched well with the location of acti-
vated astrocytes as evidenced by vimentin expression (Fig. 1A).
Figure 4. CNTF increases BDH activity in the striatum. BDH activity was studied by histochemistry on brain sections from
lenti-CNTF/lenti-lacZ rats. The lenti-LacZ striatum displays a neuropil-like staining, whereas numerous stellate cells with an
intense BDH activity are observed in the lenti-CNTF-injected striata. These cells are sometimes found in the corpus callosum
(asterisk) along the needle track or in close contactwith brain capillaries (arrowhead). Images are representative of seven animals
per group. Scale bars: top, 200m; bottom, 20m.
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We also used micro-PET imaging to per-
form a repeated analysis of FDG uptake in
the living animal. We observed a signifi-
cant decrease in FDG uptake in the stria-
tum injected with lenti-CNTF (Fig. 1C).
This decrease was consistently present
over a period of 4 months, demonstrating
the stability of the metabolic change. The
striatal level of expression of the endothe-
lial and astroglial Glut-1 measured by
Western blot, was not different between
groups ( p  0.92; ANOVA; data not
shown), indicating a preserved capa-
city of glucose transport across the
blood–brain barrier. The activity of LDH
(the enzyme that catalyzes the reversible
conversion of lactate to pyruvate) was
studied by histochemistry on brain sec-
tions from the same rats used for FDG up-
take. LDH activity (pyruvate-to-lactate re-
action) was reduced by 11% in the lenti-
CNTF injected striatum ( p  0.01;
Student’s paired t test) (Fig. 2A), which is
consistent with a reduction in the glyco-
lytic flux with CNTF. Importantly, CNTF
overexpression had no detectable effects
on peripheralmetabolism: rats injected bi-
laterally with lenti-CNTF in the striatum
had a normal weight gain during 2months
compared with control groups and had
normal blood glucose levels (arterial glyce-
mia after night fasting in the following
groups: lenti-CNTF, 1.71 0.04 g/L; lenti-
LacZ, 1.68  0.08; Veh, 1.69  0.07;
p 0.95; ANOVA).
To assess whether CNTF induced a
general decrease in striatal oxidative me-
tabolism, we measured the activity of the
mitochondrial complex IV enzyme COX,
using histochemistry on brain sections.
Quantification of specific COX activity in
the striatum showed no difference be-
tween groups ( p  0.44 between lenti-
CNTF and lenti-LacZ; p  0.92 between
Veh and lenti-LacZ; Student’s paired t
test) (Fig. 2B).
CNTF activates AMPK and increases
CPT1 expression in astrocytes in vivo
As AMPK plays a pivotal role in the coordi-
nate regulationof several energymetabolism
4
Figure 5. CNTF-activated astrocytes overexpress BDH and
SCOT.A, Stellate cellswith an intenseBDH staining (green) are
only visible in the lenti-CNTF striatum (arrowhead). BDH colo-
calizes with vimentin (red) but not with the neuronal protein
NeuN (red).B, SCOT (green), the secondenzymeon theketone
bodies pathway, is also overexpressed by CNTF-activated astro-
cytes that coexpress vimentin (red, arrowhead) but not byNeuN-
positive neurons (red). Images are representative of four to
five animals per group. Scale bars: 20m; enlarged pictures,
10m.
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pathways within the cell (Hardie et al., 2006), we determined the
level of phosphorylatedAMPK(active form) in the striatumof lenti-
CNTF-injected rats.We found thatCNTFsignificantly increased the
expression of phosphorylated AMPK (280%; p 0.001 vs lenti-
LacZ and Veh groups; Scheffe´’s test) (Fig. 3A), demonstrating a ro-
bust activation of the AMPK pathway.
In astrocytes, AMPK regulates the activity of CPT, a rate-
limiting enzyme for -oxidation of fatty acids (Blazquez et al.,
1999). In rats injected with lenti-LacZ, the expression of CPT1
(the predominant brain isoform) was low and restricted to the
neuropil. In the lenti-CNTF striatum, many stellate cells display-
ing an intense staining became apparent (Fig. 3B). These cells
coexpressed vimentin, a marker of activated astrocytes, but not
the neuronal proteinNeuN (Fig. 3B), demonstrating that CPT1 is
specifically overexpressed in CNTF-activated astrocytes.
CNTF-activated astrocytes overexpress key proteins of the
ketone bodies metabolic pathway in vivo
Using histochemistry, we next characterized the activity of BDH,
a key enzyme of the ketone bodies metabolic pathway, another
alternative energy-producing pathway. Whereas no labeling was
observed in the lenti-LacZ injected striatum, numerous cells dis-
playing an intense staining were observed in the contralateral
lenti-CNTF injected striatum. These cells were sometimes in
close contact with brain capillaries (Fig. 4). Dual-labeling exper-
iments were performed to unambiguously
identify these cells.We found a specific co-
localization of BDH with vimentin, but
not withNeuN (Fig. 5A). Similarly, SCOT,
another enzyme of the pathway responsi-
ble for the oxidation of ketone bodies, was
also specifically upregulated by CNTF-
activated astrocytes in vivo (Fig. 5B). Be-
cause ketone bodies uptake into cells is de-
pendent on MCTs, we studied the
expression of MCT1, one of the main as-
trocytic MCTs (Pierre et al., 2000). MCT1
was overexpressed in a large part of the
striatum injected with lenti-CNTF (Fig.
6A). The intensity of the labeling was uni-
formly increased in the neuropil (Fig. 6B).
Using double labeling, we found that
MCT1 immunoreactivity was present at
the surface of S100-positive cells (Fig.
6C), confirming that CNTF exposure in-
duces MCT1 overexpression at the astro-
cyte plasmamembrane. The pattern of ex-
pression of the neuronal transporter
MCT2 was not significantly modified by
CNTF (data not shown).
CNTF increases the rate of oxidation of
fatty acids and ketone bodies in vitro
Measurement of oxidative rate on intact
cells is classically performed in vitro by
quantification of released 14CO2 produced
from 14C-labeled substrates through the
TCA cycle. We took advantage of our pre-
viously described in vitromodel of CNTF-
mediated activation of astrocytes (Escartin
et al., 2006) to assess whether fatty acids
and ketone bodies were indeed used as al-
ternative energetic sources by CNTF-
activated astrocytes. First of all, we found that CNTF induced a
significant increase in the level of phosphorylated AMPK com-
pared with Veh-treated primary striatal cultures (360%; p 
0.001; unpaired t test) (Fig. 7A), an observation consistent with
the effect of CNTF obtained in vivo. To test the hypothesis that
oxidation of fatty acids was enhanced by CNTF, we quantified
14C-palmitate oxidation to 14CO2 and the formation of
14C-
intermediate metabolites (such as TCA cycle intermediates, ke-
tone bodies, etc.) in cultured cells. CNTF treatment significantly
increased 14CO2 production from 0.2 mM palmitate by 100%
( p  0.001; Scheffe´’s test) (Fig. 7B). The level of labeled acid-
soluble metabolites was not modified by CNTF, suggesting that
CNTF enhanced the flux of fatty acids through -oxidation and
the TCA cycle without increasing the storage of intermediate
metabolites. Inhibition of CPT1 by 40 M etomoxir reduced the
production of 14CO2 by 77% and the accumulation of
14C-acid
solublemetabolites by 43% relative to controls (data not shown).
This result confirms that palmitate oxidation is dependent on its
uptake into mitochondria by CPT1, which is expressed exclu-
sively by astrocytes, at a high level in vitro (data not shown).
Astrocytes can metabolize fatty acids to produce ketone bod-
ies and export them to neurons (Guzman and Blazquez, 2001).
To test the hypothesis of a cellular compartmentalization be-
tween astrocytes and neurons to achieve complete oxidation of
fatty acids (i.e., -oxidation and ketogenesis in astrocytes, ketol-
Figure 6. CNTF-activated astrocytes overexpress MCT1. A, B, MCT1 is overexpressed in the striatum of rats of the lenti-CNTF
group in the region where astrocytes are activated (arrowhead). C, MCT1 immunoreactivity is found around S100-positive
astrocytes (arrowhead), as expected for a plasma membrane transporter. Images are representative of four to five animals per
group. Scale bars: A, 1 mm; B, 100m; C, 20m.
Escartin et al. • CNTF Induces Astrocyte Metabolic Plasticity J. Neurosci., July 4, 2007 • 27(27):7094–7104 • 7099
ysis in neurons), we studied the conse-
quences of ketone bodies uptake blockade
by 3mM 4-CIN (an inhibitor of MCTs) on
the oxidation of 14C-palmitate. The inhibi-
tion of ketone bodies uptake did not reduce
14CO2 production ( p  0.99 between Veh
and Veh plus 4-CIN and p 0.91 between
CNTF andCNTF plus 4-CIN; Scheffe´’s test)
and did not increase the level of labeled in-
termediate metabolites in any group ( p 
0.32; ANOVA) (Fig. 7B), suggesting that full
fatty acids oxidation occurs within the same
cell (most likely CNTF-activated astrocytes
that express CPT1).
The rate of ketone bodies oxidationwas
evaluated by quantifying 14CO2 produc-
tion from 14C-BHB in cell cultures. CNTF
treatment significantly increased 14CO2
production from 2mM BHB by 30% ( p
0.05; unpaired t test) (Fig. 7C). Inhibition
of MCT transporters by 3 mM 4-CIN de-
creased 14CO2 production by 76% (data
not shown), demonstrating that BHB oxi-
dationwasmainly dependent on its uptake
into cells and mitochondria by MCTs.
MCT1 was expressed at a relatively low
level in culture and CNTF significantly in-
creased the expression of MCT1 in astro-
cytes (Fig. 7D), consistent with the previ-
ously observed effect in vivo.
CNTF-activated astrocytes can handle
toxic levels of extracellular palmitate
and are more resistant to
glycolytic inhibition
Fatty acid accumulation occurs in several
pathological conditions and is toxic to brain
cells (Bazan, 1970, 1971). In particular, pro-
longed exposure to palmitate induces the
death of astrocytes, via the intracellular pro-
duction of the pro apoptotic agent ceramide
(Blazquez et al., 2000). We found that addi-
tion of 0.2 mM palmitate for 24 h induced
marked morphological changes in Veh-
treated astrocytes (disappearance of thin
processes and formation of globular end-
ings) and astrocyte degeneration but had no
detectable effect on neurons (Fig. 8). In con-
trast to control astrocytes, CNTF-treated as-
trocytes were unaffected by palmitate (Fig.
8). However, palmitate was toxic to CNTF-
activated astrocytes when -oxidation was
blocked by 2mM 4-pentenoate.
The ability of CNTF-activated astrocytes
to use alternative energetic substrates besides glucose may also in-
crease their resistance to a defect in glucose use. Treatment with the
glycolysis inhibitor IAA (0.4 mM) for 10 min triggered a massive
cellular degeneration in vitro after 24 h (83% reduction; p 0.001
betweenVeh andVehplus IAA; Scheffe´’s test) (Figs. 9, 10).Neurons
andastrocyteswereaffectedandremainingastrocytesdisplayedcon-
densed, patchy processes with intense GFAP staining (Fig. 9).
CNTF-activated astrocytes were markedly more resistant to glyco-
lytic inhibition and had a normal morphology (Fig. 9). This im-
proved survival of astrocyteswas accompaniedbya rescueofMAP2-
positive neurons present in the dish 24 h after IAA exposure (Fig. 9)
so that the totalnumberof livingcellswas similar tocontrol (Fig. 10).
To evaluate whether CNTF protective effects involved the up-
take of alternative substrates that bypass the glycolysis block
(such as ketone bodies), we used 4-CIN to inhibit MCTs and
the uptake of monocarboxylates. The survival of CNTF-
Figure 7. CNTF activates AMPK and increases the rate of fatty acids and ketone bodies oxidation inmixed cultures.A, The level
of phosphorylation of AMPK is significantly increased in CNTF-treated cultures (C) comparedwith Veh (V). Blots are representative
of two to three wells per treatment from three independent cultures. B, Fatty acids oxidation was evaluated by measuring the
production of 14CO2 and acid-soluble metabolites from
14C-palmitate. CNTF increases 14C-palmitate oxidation to CO2 (***p
0.001; *p 0.05; Scheffe´’s test). On the contrary, the rate of palmitate oxidation to intermediate metabolites is not altered by
CNTF. Blockade of ketone bodies uptake by 3mM 4-CIN did not interfere with CNTF effects, suggesting that complete oxidation of
fatty acids occurs within the same cell (i.e., astrocytes). Results are means SEM of two to five dishes per group in two to four
separate cultures. C, CNTF significantly increases 14C-BHB oxidation to 14CO2 (*p 0.05 vs Veh; Student’s t test). Results are
means SEM of three to four dishes per group in four separate cultures. D, MCT1 (green) is overexpressed in CNTF-treated
cultures.MCT1 is expressedon theprocessesofGFAP-positive astrocytes (arrowhead). Imagesare representativeof threewells per
treatment on three independent cultures. Scale bars (in D): left, 50m; right, 20m.
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treated astrocytes and neurons was significantly reduced in the
presence of 4-CIN ( p  0.001 between CNTF plus IAA and
CNTF plus IAA plus 4-CIN; Scheffe´’s test) (Figs. 9, 10).
Importantly, before exposure to IAA or palmitate, CNTF-
treatment did not show any protective or proliferative effects on
cultured cells that could explain this improved survival rate. CNTF
had no significant effect on total cell densities ( p  0.97 between
CNTF- and Veh-treated wells in control conditions; Scheffe´’s test)
(Fig. 10), neuronal and astrocytic densities (Figs. 8, 9, controls), and
total content in proteins (data not shown). In addition, CNTF-
activated astrocytes were more resistant to IAA and palmitate even
when CNTF was removed from the medium during the 24 h expo-
sure to palmitate and during the 24 h period recovery after IAA
exposure (data not shown).
Discussion
CNTF-mediated activation of astrocytes involves marked
changes in their metabolic profile
We found that activation of astrocytes by CNTF induced stable
changes in the regulation of striatal energy metabolism in vivo,
including a reduction of the glycolytic flux with maintenance of
downstream oxidative steps of energy production. This result
Figure 9. CNTF-activated astrocytes are more resistant to glycolysis inhibition. In Veh-treated cultures, exposure to 0.4 mM IAA for 10 min triggers a massive degeneration of GFAP-positive
astrocytes (green) and MAP2-positive neurons (red) at 24 h compared with control conditions. In CNTF-treated cultures, the rate of survival is markedly improved for astrocytes, and neuronal
dendrites are less dystrophic. In the presence of 3mM4-CIN (IAA plus 4-CIN), CNTF looses its protective effects, and both neurons and astrocytes display a pathologicalmorphology and a low survival
rate. Images are representative of results obtained in two to three wells from three to six independent cultures. Scale bar, 50m.
Figure 8. CNTF-activated astrocytes handle toxic extracellular palmitate. Exposure to 0.2 mM BSA-bound palmitate is toxic to Veh-treated astrocytes (labeled for GFAP, green), but has no
detectable effect on MAP2-positive neurons (red). Veh-treated astrocytes exposed to palmitate have a lower density than controls (CTR) and display morphological abnormalities, visible at higher
magnification as fewer thin processes and globular endings (arrowhead). In CNTF-treated cultures, palmitate has no detectable effect onGFAP-positive astrocytes.When-oxidation is inhibited by
2 mM 4-pentenoate (4-P), CNTF-activated astrocytes are no longer resistant to palmitate exposure. Images are representative of results obtained in two to three wells from three independent
cultures. Scale bars: top, 50m; bottom,10m.
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suggested that alternative pathways may have been activated to
fuel the mitochondrial electron transfer chain. Our observation
that CNTF activated AMPK, a central regulator of energy metab-
olism, both in vivo and in vitro, reinforced this idea. In the brain,
fatty acids and ketone bodies can replace glucose as the major
source of energy in specific conditions. Astrocytes are the only
brain cell type that display a high rate of fatty acid utilization and
ketogenesis (Auestad et al., 1991; Guzman and Blazquez, 2001)
under the control of AMPK (Blazquez et al., 1999).We found that
CNTF activated AMPK and increased the expression of CPT1
(the rate-limiting enzyme for -oxidation of fatty acids) in astro-
cytes. We cannot rule out that AMPK was also activated in other
cell types, although changes inmetabolic enzymes or transporters
were restricted to astrocytes. Interestingly, it has been recently
shown that the antiobesogenic effects of CNTF resulted from the
stimulation of fat oxidation directly in skeletal muscle via an
activation of AMPK and an increased expression of CPT1 (Watt
et al., 2006b). Our observation that CNTF increased the astro-
cytic expression of MCT1, SCOT, and BDH, three key enzymes/
transporters of the ketone bodies metabolic pathway, strongly
supported the hypothesis that ketolysis in astrocytes was also
chronically enhanced by CNTF. We next provided functional
evidence that both the activity of BDH in vivo and the rate of
oxidation of fatty acids and ketone bodies in vitro were markedly
enhanced by CNTF, indicating that CNTF-activated astrocytes
do use ketone bodies and fatty acids as alternative energetic sub-
strates. We have tested the hypothesis of a cellular compartmen-
talization between astrocytes and neurons for a complete oxida-
tion of fatty acids and shown that it did not involve ketone bodies
exchange between astrocytes and neurons.
Altogether our results suggest that activation of astrocytes by
CNTF involved a specific reorganization of their metabolic pro-
file (Fig. 11) rather than a general enhancement of their oxidative
capacity, as it was proposed previously for reactive astrocytes
surrounding brain lesions (Smith, 1963; Al-Ali and Robinson,
1982). Interestingly, we have previously shown that CNTF-
activated astrocytes have enlarged endfeet around striatal capil-
laries (Escartin et al., 2006). This morphological alteration may
have an impact on blood flow and energetic supply and could
represent an additional mechanism for CNTF-activated astro-
cytes to modulate brain metabolism.
The metabolic profile of CNTF-activated astrocytes is highly
reminiscent of the immature brain that metabolizes ketone bod-
ies and fatty acids at a high rate before weaning (Edmond, 1992).
However, in the adult, these substrates are not as abundant as
during the lactating period, and they are much less abundant
than glucose. Nevertheless, given the basal concentration of free
palmitate in the adult brain parenchyma (0.06 mM) (Lipton,
1999), its oxidative rate in vitro (comparable with glucose oxida-
tive rate) (Edmond, 1992) and the ATP yield of -oxidation (3
timesmore than glucose), its oxidation can produce a substantial
amount of energy for the cell. In addition, fatty acid concentra-
tion significantly rises in some pathological situations (see next
paragraph) in which they would become a privileged energy sub-
strate. The plasma concentration of ketone bodies is even lower
(10–100 M in the feeding adult rat) (Veech et al., 2001), but
they can be produced locally from fatty acids by astrocytes them-
selves (Guzman and Blazquez, 2001). Our findings that CNTF
directly acts on astrocytes to modify their metabolic profile in
vivo and in vitro is new and suggests that CNTF may be a major
regulator of peripheral and central cellular energy metabolism.
Functional consequences of CNTF-induced brain
metabolic plasticity
Prolonged exposure to palmitate activates cell death pathways
(Ulloth et al., 2003) and leads to ceramide synthesis in astrocytes
(Blazquez et al., 2000).We found that CNTF-activated astrocytes
were totally resistant to toxic palmitate levels in vitro, even when
CNTF was removed from the medium during the 24 h exposure
to palmitate. This result indicates that CNTF does not protect
astrocytes through a delayed anti-cell death action but rather by a
preexisting remodeling of the metabolic status of astrocytes. We
also found that blockade of -oxidation abolishes the protective
effect of CNTF. Because palmitate -oxidation is performed
twice as efficiently in CNTF-activated astrocytes, our result sug-
gests that the increased oxidation of fatty acids by CNTF-
activated astrocytes prevents their accumulation and reduces
their availability for ceramide neosynthesis (Fig. 11). This is to-
tally consistent with the very recent observation that CNTF at-
tenuates ceramide accumulation insidemyocytes after lipid infu-
sion (Watt et al., 2006a). Our results are of importance because a
massive release of free fatty acids from phospholipids in the
plasma membrane occurs in acute pathological conditions such
as brain trauma and ischemia or a chronic neurodegenerative
disease such as Alzheimer’s disease (Phillis and O’Regan, 2004).
All of these conditions also involvemetabolic defects (Beal, 2000)
and induce activation of astrocytes. In this regard, astrocyte acti-
vation appears to be a very efficient adaptive response to face a
shortage in energetic supply and accumulation of toxic metabo-
lites at the same time.
We also provided evidence that CNTF-activated astrocytes
were highly resistant to glycolytic inhibition and that this effect
was partially mediated by the transport of monocarboxylates. It
was not possible to determine which of the monocarboxylates
(ketone bodies, lactate, or pyruvate) was involved in CNTF-
protective effects. However, the production of pyruvate and lac-
tate is dependent on the glycolytic flux, and their concentrations
may be lowered by IAA exposure. On the contrary, ketone bodies
are totally independent from glycolysis, and their rate of oxida-
tion was significantly increased with CNTF, making them more
suitable candidates.
Figure 10. Quantification of CNTF protective effects against IAA. Cell counts confirm that
CNTF treatment confers strong protection against IAA, an effect that is mainly dependent on MCT
transporters. Data are expressed asmean SEM; ***p0.001 versus control Veh; CNTF andCNTF
plus IAA; Scheffe´’s test. Data are from threewells per condition in two separate cultures.
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The ability to efficiently use alternative substrates besides glucose
may improve the resistance to a shortage in glucose supply, or inhi-
bition of glycolysis/pyruvate dehydrogenase (PDH) complex. Oxi-
dation of ketone bodies and fatty acids produces acetyl-CoA,
FADH2, andNADH,H
 that candirectly fuel theTCAcycle and the
mitochondrial electron transport chain, by-
passing glycolysis and PDH. Indeed, ketone
bodies protect brain cells against situations
of energy impairment, suchas glucosedepri-
vation, glycolytic inhibitiononhippocampal
slices from young rats (Izumi et al., 1998),
ischemia (Marie et al., 1987), and blockade
of mitochondrial complex I by MPTP in
mice (Tieu et al., 2003). More generally, ke-
tolysis seems to bemore efficient than glyco-
lysis to fuel the TCA cycle because it is per-
formed in three rapid reactions within the
mitochondria,whereasglycolysis requires10
cytoplasmic reactions and mitochondrial
uptake of NADH,H, pyruvate, and lactate
(Veech et al., 2001). Most importantly, gly-
colysis requires ATP investment, which is
problematic in conditions of energy
depletion.
CNTF-activated astrocytes as
neuroprotective agents
The activation of astrocytes is thought to
induce neuronal demise in diverse patho-
logical situations through release of toxic
molecules, reversal of glutamate transport,
or inhibition of axonal regrowth (Kalman,
2004). Our results, however, indicate that
CNTF-activated astrocytes acquire an im-
proved capacity to deal withmetabolic im-
pairment that leads to an increased neuro-
nal survival. We have demonstrated
previously that CNTF activation of astro-
cytes improved handling of toxic levels of
extracellular glutamate (Escartin et al.,
2006). Excitotoxicity is also involved in
several pathological situations and is even
exacerbated by metabolic dysfunction.
The fact that CNTF-activated astrocytes
aremore efficient to copewith both insults
may underlie the important neuroprotec-
tive effects of CNTF in various in vivo
models of excitotoxic cell death (Anderson
et al., 1996; de Almeida et al., 2001), isch-
emia (Hermann et al., 2001), and chronic
metabolic impairment (Mittoux et al.,
2000, 2002). CNTF has been tested clini-
cally for the treatment of amyotrophic lat-
eral sclerosis (Aebischer et al., 1996) and
Huntington’s disease (Bachoud-Levi et al.,
2000), in which glutamate toxicity and
metabolic deficiency play a key role (Beal,
1992). Considering the beneficial effects
observed in the present study, our results
strongly support the concept of testing
CNTF as a therapeutic candidate for these
incurable diseases.
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